Acorda Therapeutics, Inc. ACOR will present new analyses of
pharmacokinetic data from a Phase 1 clinical trial of rHIgM22, a
remyelinating antibody being studied for the treatment of multiple
sclerosis (MS), and five-year post-marketing safety data on AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg at the 31st
Congress of the European Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS). The meeting is being held in Barcelona,
Spain, October 7 - 10.
"Acorda is committed to researching novel therapies that can improve the
lives of people with multiple sclerosis. The scientific data being
presented at ECTRIMS feature new information about our investigational
and marketed MS therapies," said Enrique Carrazana, M.D., Chief Medical
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in